Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 β-lactamase

Yohei Doi, David L. Paterson, Jennifer M. Adams-Haduch, Hanna E. Sidjabat, Alexandra O'Keefe, Andrea Endimiani, Robert A. Bonomo

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Here we describe three Escherichia coli clinical isolates with reduced susceptibility to cefepime. Sequencing of the blaCMY genes revealed two novel variants (CMY-33 and -44) with two- to four-amino-acid deletions in the H-10 helix. The deletions were responsible for 12- to 24-fold increases in the MICs of cefepime.

Original languageEnglish
Pages (from-to)3159-3161
Number of pages3
JournalAntimicrobial agents and chemotherapy
Volume53
Issue number7
DOIs
Publication statusPublished - 01-07-2009
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Reduced susceptibility to cefepime among Escherichia coli clinical isolates producing novel variants of CMY-2 β-lactamase'. Together they form a unique fingerprint.

  • Cite this